Value of shared preclinical safety studies – The eTOX database

摘要

class="kwd-title">Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CDISC, Clinical Data Interchange Standards Consortium; CRO, contract research organisation; DILI, drug induced liver injury; EFPIA, European Federation of Pharmaceutical Industries and Associations; eTOX, integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities; FN, false negative; FP, false positive; GLP, good laboratory practice; ICH, International Conference on Harmonisation; IMI, Innovative Medicines Initiative; INHAND, International Harmonization of Nomenclature and Diagnostic Criteria; IT, information technology; MCC, Matthews correlation coefficient; OECD, Organisation for Economic Co-operation and Development; PDF, Portable Document Format; PDF/A, ISO-standardized version of PDF specialized for the digital preservation of electronic documents.; QA, quality assurance; SEND, Standard for Exchange of Nonclinical Data; SME, small-to-medium enterprise; TN, true negative; TP, true positive; ULN, upper limit of normal class="kwd-title">Keywords: Data sharing, Toxicology, Data mining, Biomarkers, Ontology class="head no_bottom_margin" id="abs0015title">AbstractA first analysis of a database of shared preclinical safety data for 1214 small molecule drugs and drug candidates extracted from 3970 reports donated by thirteen pharmaceutical companies for the eTOX project () is presented. Species, duration of exposure and administration route data were analysed to assess if large enough subsets of homogenous data are available for building in silico predictive models. Prevalence of treatment related effects for the different types of findings recorded were analysed. The eTOX ontology was used to determine the most common treatment-related clinical chemistry and histopathology findings reported in the database. The data were then mined to evaluate sensitivity of established in vivo biomarkers for liver toxicity risk assessment. The value of the database to inform other drug development projects during early drug development is illustrated by a case study.